Novavax Develops a Stronger Immunogenic Vaccine Against Coronavirus
Novavax Inc has started Phase 1 clinical trials of a novel coronavirus vaccine candidate and enrolled the trial’s first participants in Australia. CSO Gregory Glenn explains that by using an adjuvant he and his team were able to develop a stronger immunogenic vaccine to produce neutralizing antibodies for protection. Count accuracy is crucial for vaccine development and to monitor the impacts of immunological agent responses. Nexcelom’s Cellometer Auto T4 System can be seen aiding these endeavors and showing analyzed images of these functional responses.
Gene and Virus-based Therapeutic Advancements
The Mayo Clinic Cancer Center’s Gene and Virus Therapy Shared Resource has worked for the last decade cultivating knowledge and extending expertise to advance ten pre-clinical research projects into human clinical trials. Director, Mark J. Federspiel, Ph.D. explains the roadblocks to these efforts stating, “we end up dealing with a whole variety of issues mainly around manufacturing and the toxicology/pharmacology studies that the Food Drug Administration requires”. The Gene and Virus Therapy Shared Resource has broken down these barriers by continuously working in partnership with the FDA to support the design and production of appropriate protocols and efficacy data as well as toxicological and pharmacological characterization.
This academic lab’s collaborative efforts enable promising concepts for virus-based therapies to come to light by affording the resources to satisfy FDA toxicology and pharmacology requirements for production. The Shared Resources’ Quality Assurance component supports all of this skilled research in biochemistry, molecular biology, cell biology, and virology by streamlining record maintenance and the FDA reporting process. In this video, an operator can be seen loading a sample on the Cellometer Auto T4 to receive fluorescent imaging and analysis, critical to the lab’s standardized protocols for manufacturing.
Leukemia Versus the Measles Virus
Stacy Erholtz battled multiple myeloma for a decade before doctors at the Mayo Clinic Cancer Research Center decided to take a roundabout route of treatment for her cancer of the blood. Scientists injected Stacy and five other patients with a high-dosage treatment of the measles virus. Similar to the measles vaccine, the measles virus works to specifically damage cancer cells in immune-deficient patients while ignoring healthy tissues. Stacy is the first case of remission occurring where the cancer was spread throughout the patient. Unsurprisingly, the dosage is the key factor for efficacy, and to obtain the correct dosage, the correct cell line must be accurately counted. In the video, a sample is shown being pipetted into ports on a Cellometer dual-chamber slide for rapid and accurate cell counting.